IP Library Granted Patent US 11,690,817
Granted Patent B2
US 11,690,817 · App. 17/389,586 · Granted Jul 4, 2023

Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use

Inventor: Gary Millet (Salt Lake City, UT)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/19A61K9/0053A61K31/047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,690,817
App. No.
17/389,586
Granted
Jul 4, 2023
Kind
B2
Abstract

Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and from about 49.5% to about 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.

Claims (43)

1. A composition for administering ketone bodies to a subject, comprising:

a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of R-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate includes:

at least one R-beta-hydroxybutyrate salt;

at least one S-beta-hydroxybutyrate salt; and

at least one of R- or S-beta-hydroxybutyric acid,

wherein the non-racemic mixture comprises 75% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts,

wherein the non-racemic mixture comprises 0.1% to 25% by molar equivalents of the at least one of R- or S-beta-hydroxybutyric acid.

2. The composition of claim 1 , wherein the non-racemic mixture contains from 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and 49.5% to 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.

3. The composition of claim 1 , wherein the non-racemic mixture contains from 51% to 99% by enantiomeric equivalents of R-beta-hydroxybutyrate and 49% to 1% by enantiomeric equivalents of S-beta-hydroxybutyrate.

4. The composition of claim 1 , wherein the non-racemic mixture contains from 52% to 98% by enantiomeric equivalents of R-beta-hydroxybutyrate and 48% to 2% by enantiomeric equivalents of S-beta-hydroxybutyrate.

5. The composition of claim 1 , wherein the non-racemic mixture contains from 53% to 97% by enantiomeric equivalents of R-beta-hydroxybutyrate and 47% to 3% by enantiomeric equivalents of S-beta-hydroxybutyrate.

6. The composition of claim 1 , wherein the non-racemic mixture comprises 80% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts and 20% to 0.1% by molar equivalents of R-beta-hydroxybutyric acid and/or S-beta-hydroxybutyric acid.

7. The composition of claim 1 , wherein the non-racemic mixture comprises 85% to about 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts and 15% to 0.1% by molar equivalents of R-beta-hydroxybutyric acid and/or S-b eta-hydroxybutyric acid.

8. The composition of claim 1 , wherein the non-racemic mixture comprises 90% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts and 10% to 0.1% by molar equivalents of R-beta-hydroxybutyric acid and/or S-beta-hydroxybutyric acid.

9. The composition of claim 1 , wherein the non-racemic mixture comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of R-beta-hydroxybutyrate and/or S-beta-hydroxybutyrate.

10. The composition of claim 1 , further comprising at least one short chain fatty acid having less than 6 carbons, or a mono-, di- or triglyceride of the at least one short chain fatty acid.

11. The composition of claim 1 , further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.

12. A composition for administering ketone bodies to a subject, comprising:

a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of R-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate includes:

at least one R-beta-hydroxybutyrate salt or ester;

at least one S-beta-hydroxybutyrate salt or ester; and

at least one of R- or S-beta-hydroxybutyric acid,

wherein the non-racemic mixture comprises 75% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts,

wherein the non-racemic mixture comprises 0.1% to 25% by molar equivalents of the at least one of R- or S-beta-hydroxybutyric acid, and

wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository.

13. The composition of claim 12 , wherein the non-racemic mixture contains from 50.5% to 99.5% by enantiomeric equivalents of R-beta-hydroxybutyrate and 49.5% to 0.5% by enantiomeric equivalents of S-beta-hydroxybutyrate.

14. The composition of claim 12 , wherein the non-racemic mixture comprises 85% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts and 15% to 0.1% by molar equivalents of R-beta-hydroxybutyric acid and/or S-beta-hydroxybutyric acid.

15. The composition of claim 12 , wherein the non-racemic mixture comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of R-beta-hydroxybutyrate and/or S-beta-hydroxybutyrate, and wherein the composition is a powder.

16. The composition of claim 12 , further comprising at least one supplement selected from vitamin, mineral, nootropic, and herbal supplement.

17. A composition for administering ketone bodies to a subject, comprising:

a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository; and

a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of R-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate includes:

at least one R-beta-hydroxybutyrate salt or R-beta-hydroxybutyrate ester;

at least one S-beta-hydroxybutyrate salt or S-beta-hydroxybutyrate ester; and

at least one of R- or S-beta-hydroxybutyric acid,

wherein the non-racemic mixture comprises 75% to 99.9% by molar equivalents of combined R-beta-hydroxybutyrate and S-beta-hydroxybutyrate salts,

wherein the non-racemic mixture comprises 0.1% to 25% by molar equivalents of the at least one of R- or S-beta-hydroxybutyric acid.

18. A kit for administering ketone bodies to a subject, comprising:

a composition as in claim 1 ;

a container in which the composition is placed; and

a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 0.5 g to about 25 g of the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate.

19. The kit of claim 18 , wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, and keg.

20. The kit of claim 18 , wherein the measuring device is selected from the group consisting of cup, scoop, syringe, dropper, spatula, spoon, and colonic irrigation device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2021
From: MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 057030/0682 →
Continuity (7)
Continuation 16783844 · Feb 6, 2020
Continuation In Part 16409501 · May 10, 2019
Continuation In Part 16272165 · Feb 11, 2019
Continuation In Part 16224408 · Dec 18, 2018
Division 15936820 · Mar 27, 2018
Provisional Application 62590063 · Nov 22, 2017
Related Publication 20210353572A1 · Nov 18, 2021
Cited By (14)
US 12,186,297 US 12,251,362 US 12,329,734 US 12,350,243 US 12,433,912 US 12,439,945 US 12,472,200 US 12,496,283 US 12,521,378 US 12,533,331 US 12,533,346 US 12,551,455 US 12,599,579 US 12,622,889